Hospital News Hubb
Advertisement Banner
  • Home
  • News
  • Technology
  • Contact
No Result
View All Result
  • Home
  • News
  • Technology
  • Contact
No Result
View All Result
Wellnessnewshubb
No Result
View All Result
Home Technology

New approach may serve as the basis for universal flu vaccines

admin by admin
November 25, 2022
in Technology



Claudia Arevalo and colleagues have developed a mRNA lipid nanoparticle vaccine that contains antigens from all 20 known subtypes of influenza A and B viruses, a strategy that may serve as the basis for universal flu vaccines.

Their vaccine produced high levels of cross-reactive and subtype-specific antibodies in mice and ferrets and could protect animals against disease symptoms and death after infection with both antigenically matched and mismatched strains of influenza. Even with increased global surveillance, it is difficult to predict which flu strain will cause the next flu pandemic, making a universal vaccine important.

The approach by Arevalo et al. differs from previous attempts to craft a universal flu vaccine by including antigens specific to each subtype, rather than just a smaller set of antigens shared among subtypes. Following on the success of mRNA vaccines against SARS-CoV-2, the researchers prepared 20 different nanoparticle encapsulated mRNAs, each encoding a different hemagglutinin antigen – a highly immunogenic flu protein that helps the virus enter cells. Antibody levels remained mostly stable four months after vaccination in the mice. Multivalent protein vaccines produced using more traditional methods elicited fewer antibodies and were less protective compared to the multivalent mRNA vaccine in the animals.

In a related Perspective, Alyson Kelvin and Darryl Falzarano discuss the results, noting that “questions remain regarding the regulation and approval pathway of such a vaccine that targets viruses of pandemic potential but are not currently in human circulation.”

Source:

American Association for the Advancement of Science (AAAS)

Journal reference:

Arevalo, C.P., et al. (2022) A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science. doi.org/10.1126/science.abm0271.



Source link

Tags: AntibodiesFluInfluenzaNanoparticlePandemicProteinVaccineVirus
Previous Post

Department of Justice opens investigation into real estate tech company accused of collusion with landlords

Next Post

The potential of Sofosbuvir against COVID-19 neurological symptoms

Next Post

The potential of Sofosbuvir against COVID-19 neurological symptoms

Recommended

Climate activists set to pressure Biden with Congress divided

4 months ago

New technologies and recent advances in the study of T cells and T-cell epitope discovery in food allergy research

4 months ago

© 2022 Hospital News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Technology
  • Contact

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Technology
  • Contact

© 2022 Hospital News Hubb All rights reserved.

Our Spring Sale Has Started

You can see how this popup was set up in our step-by-step guide: https://wppopupmaker.com/guides/auto-opening-announcement-popups/